C2I 2022 Medical & Healthcare winner - ProstaPalp
An innovative new device for identifying prostate cancer could soon offer a more efficient, safer, and lower cost alternative to current diagnostic methods

It is estimated that one man dies every 45 minutes from prostate cancer, yet over three quarters of men who agree to a biopsy will not have the disease.
This can be problematic, with risks that include bleeding, infection and erectile disfunction. It can also be expensive, with the UK accounting for 220,000 prostate biopsies annually at a cost of £355 per procedure. In Europe, 1.3 million biopsies are carried out at €2,392 per biopsy, and in the USA one million biopsies occur at a cost of $2,300 per biopsy.
According to Professor Alan McNeill, Chief Medical Officer and co-founder of Intellipalp Dx, winners of C2I’s Medical & Healthcare category, there is also an environmental penalty to biopsies that return negative results.
“MRIs, the gold standard for prostate cancer diagnosis, require specialists to both operate and interpret the results while the technique consumes as much energy as 50 UK homes - over 13 operational hours - a significant environmental impact given the percentage of unnecessary MRIs delivered daily,” he said.
Register now to continue reading
Thanks for visiting The Engineer. You’ve now reached your monthly limit of premium content. Register for free to unlock unlimited access to all of our premium content, as well as the latest technology news, industry opinion and special reports.
Benefits of registering
-
In-depth insights and coverage of key emerging trends
-
Unrestricted access to special reports throughout the year
-
Daily technology news delivered straight to your inbox
Comment: The UK is closer to deindustrialisation than reindustrialisation
"..have been years in the making" and are embedded in the actors - thus making it difficult for UK industry to move on and develop and apply...